Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of Acute myeloid leukemia
Abstract Hereby, we aimed to investigate the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) and Vascular Endothelial Factor-C (VEGF-C) besides the methylation of PTGS2 in AML patients. VEGF-C and PTGS2 expression analysis were evaluated in newly diagnosed AML patients and healthy controls by quantitative Reverse Transcriptase PCR method. Also, PTGS2 methylation status was evaluated by Methylation-Sensitive High-Resolution Melting Curve Analysis (MS-HRM). While 34% of patients were female, the mean age of the patients was 43.41 ± 17.60 years suffering mostly from M4 (48.21%) type of AML. Although methylation level between patients and controls was not significantly different, none of the normal controls showed methylation in the PTGS2 promoter. PTGS2 and VEGF-C levels were elevated in AML cases and correlated with WBC, Platelet, and Hemoglobin levels. The survival of patients with overexpressed VEGF-C and PTGS2 was poorer than others. It can be concluded that PTGS2 and especially VEGF-C expression but not PTGS2 methylation can be considered as diagnostic biomarkers for AML..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Molecular biology reports - 49(2022), 8 vom: 22. Juni, Seite 7849-7862 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kiani-Zadeh, Masoumeh [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
DNA methylation |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature B.V. 2022 |
|---|
| doi: |
10.1007/s11033-022-07615-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2079201875 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2079201875 | ||
| 003 | DE-627 | ||
| 005 | 20230518174357.0 | ||
| 007 | tu | ||
| 008 | 221220s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11033-022-07615-7 |2 doi | |
| 035 | |a (DE-627)OLC2079201875 | ||
| 035 | |a (DE-He213)s11033-022-07615-7-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 42.00 |2 bkl | ||
| 100 | 1 | |a Kiani-Zadeh, Masoumeh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Studying the potential of upregulated PTGS2 and VEGF-C besides hyper-methylation of PTGS2 promoter as biomarkers of Acute myeloid leukemia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature B.V. 2022 | ||
| 520 | |a Abstract Hereby, we aimed to investigate the expression of prostaglandin-endoperoxide synthase 2 (PTGS2) and Vascular Endothelial Factor-C (VEGF-C) besides the methylation of PTGS2 in AML patients. VEGF-C and PTGS2 expression analysis were evaluated in newly diagnosed AML patients and healthy controls by quantitative Reverse Transcriptase PCR method. Also, PTGS2 methylation status was evaluated by Methylation-Sensitive High-Resolution Melting Curve Analysis (MS-HRM). While 34% of patients were female, the mean age of the patients was 43.41 ± 17.60 years suffering mostly from M4 (48.21%) type of AML. Although methylation level between patients and controls was not significantly different, none of the normal controls showed methylation in the PTGS2 promoter. PTGS2 and VEGF-C levels were elevated in AML cases and correlated with WBC, Platelet, and Hemoglobin levels. The survival of patients with overexpressed VEGF-C and PTGS2 was poorer than others. It can be concluded that PTGS2 and especially VEGF-C expression but not PTGS2 methylation can be considered as diagnostic biomarkers for AML. | ||
| 650 | 4 | |a PTGS2 protein, human | |
| 650 | 4 | |a Vascular endothelial growth factor C | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a DNA methylation | |
| 650 | 4 | |a Real-time polymerase chain reaction | |
| 650 | 4 | |a Leukemia, myeloid, acute | |
| 700 | 1 | |a Rezvany, Mohammad Reza |4 aut | |
| 700 | 1 | |a Namjoo, Soodeh |4 aut | |
| 700 | 1 | |a Barati, Mahmood |4 aut | |
| 700 | 1 | |a Mohammadi, Mohammad Hossein |4 aut | |
| 700 | 1 | |a Ghasemi, Bahare |4 aut | |
| 700 | 1 | |a Tabatabaei, Tahere |4 aut | |
| 700 | 1 | |a Ghavamzadeh, Ardeshir |4 aut | |
| 700 | 1 | |a Zaker, Farhad |4 aut | |
| 700 | 1 | |a Teimoori-Toolabi, Ladan |0 (orcid)0000-0002-6588-9774 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular biology reports |d Springer Netherlands, 1960 |g 49(2022), 8 vom: 22. Juni, Seite 7849-7862 |w (DE-627)129400998 |w (DE-600)186544-4 |w (DE-576)014783312 |x 0301-4851 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:8 |g day:22 |g month:06 |g pages:7849-7862 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11033-022-07615-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-CHE | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 936 | b | k | |a 42.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 8 |b 22 |c 06 |h 7849-7862 | ||